BD Rhapsody™ ATAC-Seq Assay Helps Researchers Understand DNA Regulation and Enable Advancements in Precision Medicine FRANKLIN LAKES, N.J., June 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases. Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell multiomic research. Researchers worldwide are currently using innovative approaches to study multiple aspects of health and disease at a single-cell level. In the ever-evolving field of biological research, the newly launched BD Rhapsody™ Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay enables scientists to perform single-cell analysis of the epigenome – the set of chemical marks, or epigenetic changes, on the DNA in a single cell that holds critical clues about mechanisms of disease. Adding an epigenomic layer-view will play a crucial role in helping researchers track and understand how environmental factors impact the DNA and corresponding cell function. By gaining such knowledge about DNA, scientists can deepen their understanding of how diseases progress and apply those learnings to develop effective therapies. "As part of our comprehensive and growing portfolio of single-cell multiomics solutions, the BD Rhapsody™ ATAC-Seq Assay, together with other recently launched BD single-cell assays, enables our customers to more deeply understand even rare cells that are often the 'key culprits' in pathologies like cancer and infectious diseases," said Steve Conly, worldwide president of Biosciences at BD. "By providing a complete portfolio of multiomics research tools, we are paving the way for scientists to tackle major challenges and develop innovative therapies leading to advancements in precision medicine. Our new single-cell multiomics assays, together with the BD Rhapsody™ portfolio of reagents and bioinformatics tools, support our aim to provide a true end-to-end ecosystem of single-cell multiomics solutions for researchers – whether at academic research, biopharmaceutical or core lab facilities." Commercially available globally today, the BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Next Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay are designed to be used on the BD Rhapsody™ Single-Cell Analysis System – a gentle, microwell-based instrument for conducting single cell research. The BD single-cell multiomics portfolio is available for purchase from BD representatives, or in some regions, through our ecommerce portal. More information is available at bdbiosciences.com or through BD sales representatives. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Troy Kirkpatrick Adam Reiffe VP, Public Relations Sr. Director, Investor Relations 858.617.2361 201.847.6927 [email protected] [email protected] BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company)) Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-bd-research-tool-helps-scientists-study-cells-that-are-often-key-culprits-in-the-development-of-cancer-and-infectious-diseases-302182270.html SOURCE BD (Becton, Dickinson and Company)
New BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...